Cell Medx Corp (CMXC) 0.2010 $CMXC
Cell MedX Corp. (CMXC) Engages Nutrasource Diagnostics Inc. to Commence Clinical Trials in Canada
Marketwired - Tue Mar 22, 2:23PM CDT
Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"
is pleased to announce that it has engaged Nutrasource Diagnostics Inc. ("NDI" to commence clinical trials of its innovative and proprietary technology branded under the trade name eBalance. The intent of the upcoming trial is to assess and quantify eBalance's ability to alter key metabolic pathways targeting improved blood sugar control. The trial will be conducted at several sites across Canada, after review and approval from Health Canada and a central Research Ethics Board (REB).
Cell MedX Corp. Signs a Loan Agreement
Marketwired - Wed Mar 09, 4:39PM CST
Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company", announces that on March 3, 2016 it has entered into a loan agreement (the "Loan Agreement" for a loan in the principal amount of $50,000 (the "Loan".
Cell MedX Corp. Introduces Ongoing eBalance Pro Trial Observations Online
Marketwired - Mon Jan 25, 8:01AM CST
Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company", a development stage company focused on the commercialization of therapeutic devices for patients with diseases such as diabetes, today advises it now offers access to ongoing observations of actual eBalance Professional (Pro) Series users.
Cell MedX Corp. Rolls Out eBalance Pro Series Device for Diabetes Research
Marketwired - Mon Jan 11, 8:01AM CST
Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company", a development stage company focused on the commercialization of therapeutic devices for patients with diseases such as diabetes, is pleased to announce that as of late 2015 it had received and successfully tested its first eBalance Professional Series (Pro) device.
Cell MedX Corp. Adds Team Members as Report of New Study on US Diabetes Growth Emerges
Marketwired - Wed Sep 16, 8:02AM CDT
Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company" a development stage company focused on the discovery, development and commercialization of therapeutic devices for patients with diseases such as diabetes wishes to advise of recent events in both the diabetes sector and related corporate activities.
Critical Information for Investors of Cell MedX Corp - Due Diligence Report
ACCESSWIRE - Thu Sep 10, 7:40AM CDT
NEW YORK, NY / ACCESSWIRE / September 10, 2015 / Cell MedX Corp. (OTCQB: CMXC) shares were up slightly in yesterday's session, closing at $.22 per share. On unusually heavy volume the shares traded in a range of $.21 to $.39 during the day.
Interest Rate Decision Hasn't Phased Micro Cap Stocks
ACCESSWIRE - Wed Sep 09, 11:21AM CDT
CORAL GABLES, FL / ACCESSWIRE / September 9, 2015 / This has been a looming issue for the better part of the last few months: The Fed's decision on what to do about interest rates in the US. The decision will be made known next week but according to some, the real "drama" that some had expected to see in other markets like the bond or even treasuries may simply be a non-event. Doug Duncan, chief economist for Fannie Mae recently told Yahoo Finance's Mike Santoli, "Expectations for a Fed hike built into futures prices suggest there's still only something like 30% chance assigned to a September move. If the Fed wants market expectations more aligned with its policy intentions before a rate change, then you would make the argument that they'll put it off."
ORMP: 7.99 (-0.03), LLY: 81.97 (-0.01)
Cell MedX Corp. (CMXC) Enters Into an Option Agreement With Its President and CEO
Marketwired - Tue Aug 11, 5:40PM CDT
Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company", a development stage company focused on the discovery, development and commercialization of therapeutic devices for patients with diabetes, announced that its Board of Directors has approved the grant of options (the "Options" to purchase up to 2,500,000 shares of common stock to its President and CEO, Mr. Frank E. McEnulty.
Cell MedX Corp. (CMXC) Initiates Discussions With Industry Specialists at Worrell Design
Marketwired - Tue Aug 04, 8:02AM CDT
Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company" a development stage company focused on the discovery, development and commercialization of therapeutic devices for patients with diseases such as diabetes, is pleased to advise of entry into discussions with noted multiple award-winning international product design firm, Worrell Design Inc. ("Worrell".
Cell MedX Corp. (CMXC) Advances Development Timeline
Marketwired - Mon Jul 20, 8:01AM CDT
Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company" an early development stage company focused on the discovery, development and commercialization of therapeutic devices for patients with diseases such as diabetes is pleased to update the timeline of its previously announced clinical trials regarding its innovative and proprietary technology branded under the trade name e-Balance.
Cell MedX plans to commence clinical trials for e-Balance
M2 - Wed Jul 08, 4:56AM CDT
Cell MedX Corp (OTCQB: CMXC) announced on Tuesday that efforts are underway to commence clinical trials of its proprietary technology branded under the trade name e-Balance, designed for the treatment of diabetes.
Cell MedX Corp. (CMXC) Mobilizes Efforts to Commence Clinical Trials
Marketwired - Tue Jul 07, 8:02AM CDT
Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company" is pleased to announce that efforts are underway to commence clinical trials of its innovative and proprietary technology branded under the trade name e-Balance. Designed for the treatment of diabetes, the intent of the upcoming trials is to accurately measure and quantify e-Balance's ability to alter key metabolic pathways targeting improved blood sugar control.
3 Small-Cap Biotech Stocks That Are Challenging the Status Quo
ACCESSWIRE - Mon Jun 29, 8:01AM CDT
WHITEFISH, MT / ACCESSWIRE / June 29, 2015 / Small-cap biotech stocks have been top performers so far this year, with the PowerShares S&P SmallCap Healthcare ETF (NASDAQ: PSCH) returning 25%, which is 5x better than the SPDR S&P 500 ETF's (NYSE: SPY) 5% return. Investors may want to consider adding exposure to this asset class given its outperformance and lower correlation with the overall U.S. equity market.
SPY: 216.65 (unch), PSCH: 73.91 (+0.21), AXDX: 19.54 (-0.10)
Cell MedX Corp. (CMXC) Engages TDM Financial to Generate Awareness
Marketwired - Thu Jun 25, 8:01AM CDT
Cell MedX Corp. (OTCQB: CMXC), (the "Company" is pleased to announce it has retained TDM Financial to provide marketing, outreach, and consulting services. TDM Financial owns and operates the SECFilings.com website, a leading financial network with over 600,000 registered members.
Cell MedX Corp. (CMXC) Announces Additional Results of Preliminary Analysis of Metabolomic Assays in Phase 1 Pilot Clinical Trial
Marketwired - Mon Apr 13, 7:01AM CDT
Cell MedX Corp. (OTCQB: CMXC), (the "Company" is pleased to announce additional results of the ongoing analysis of metabolomic assays taken during the Phase 1 pilot clinical trial.
Penny Stocks Research for WINDSTREAM, Fastfunds Financial, ScripsAmerica, OSL Holdings, AVRA, and Cell MedX
PR Newswire - Fri Apr 10, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: WINDSTREAM (OTCMKTS:WSTI), Fastfunds Financial (OTCMKTS:FFFC), ScripsAmerica (OTCMKTS:SCRC), OSL Holdings (OTCMKTS:OSLH), AVRA (OTCBB:AVRN), and Cell MedX (OTCBB:CMXC).
Cell MedX begins trading on OTCQB venture stage marketplace from 18 February
M2 - Thu Feb 19, 6:31AM CST
Cell MedX Corp (OTC PINK: CMXC) (OTCQB: CMXC) announced on Wednesday the receipt of an approval from the OTC Markets to upgrade to the OTCQB venture stage marketplace.
Cell MedX Corp. (CMXC) Disavows Coverage by The Moskowitz Report and The SmallCap Network
Marketwired - Tue Jan 27, 2:58PM CST
Cell MedX Corp. (OTC PINK: CMXC), (the "Company" has become aware of a paid report on the Company prepared and published by The Moskowitz Report dated Winter 2015, and additional reports on the Company prepared by James E. Brumley as a contributor for, and published by, the Small Cap Network dated January 13, 2015, January 21, 2015, and January 26, 2015. The Company believes that the above referenced reports do not provide an accurate portrayal of the Company, its business or its future prospects. Furthermore, the Company has not approved, authorized or participated in the creation of the reports prepared and published by The Moskowitz Report, the Small Cap Network, or any other third parties. The Company advises investors not to rely on these reports for information regarding the Company.
Cell MedX engages The Metabolomics Innovation Centre to explore metabolic foundations of diabetes management platform
M2 - Tue Jan 27, 3:37AM CST
Cell MedX Corp (OTC: CMXC), an early development stage company focused on the discovery, development and commercialisation of therapeutic products to help manage the illness and related complications of diseases like diabetes, announced on Monday that it has engaged the Metabolomics Innovation Centre at the University of Alberta (TMIC) to conduct metabolomics profiling of blood samples collected during the discovery phase of the pilot trial, which it commenced on 9 January 2015.
Cell MedX Corp. (CMXC) Engages Nutrasource Diagnostics Inc. to Commence Clinical Trials in Canada
Marketwired - Tue Mar 22, 2:23PM CDT
Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"
is pleased to announce that it has engaged Nutrasource Diagnostics Inc. ("NDI" to commence clinical trials of its innovative and proprietary technology branded under the trade name eBalance. The intent of the upcoming trial is to assess and quantify eBalance's ability to alter key metabolic pathways targeting improved blood sugar control. The trial will be conducted at several sites across Canada, after review and approval from Health Canada and a central Research Ethics Board (REB). Cell MedX Corp. Signs a Loan Agreement
Marketwired - Wed Mar 09, 4:39PM CST
Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"
, announces that on March 3, 2016 it has entered into a loan agreement (the "Loan Agreement" for a loan in the principal amount of $50,000 (the "Loan". Cell MedX Corp. Introduces Ongoing eBalance Pro Trial Observations Online
Marketwired - Mon Jan 25, 8:01AM CST
Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"
, a development stage company focused on the commercialization of therapeutic devices for patients with diseases such as diabetes, today advises it now offers access to ongoing observations of actual eBalance Professional (Pro) Series users. Cell MedX Corp. Rolls Out eBalance Pro Series Device for Diabetes Research
Marketwired - Mon Jan 11, 8:01AM CST
Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"
, a development stage company focused on the commercialization of therapeutic devices for patients with diseases such as diabetes, is pleased to announce that as of late 2015 it had received and successfully tested its first eBalance Professional Series (Pro) device. Cell MedX Corp. Adds Team Members as Report of New Study on US Diabetes Growth Emerges
Marketwired - Wed Sep 16, 8:02AM CDT
Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"
a development stage company focused on the discovery, development and commercialization of therapeutic devices for patients with diseases such as diabetes wishes to advise of recent events in both the diabetes sector and related corporate activities. Critical Information for Investors of Cell MedX Corp - Due Diligence Report
ACCESSWIRE - Thu Sep 10, 7:40AM CDT
NEW YORK, NY / ACCESSWIRE / September 10, 2015 / Cell MedX Corp. (OTCQB: CMXC) shares were up slightly in yesterday's session, closing at $.22 per share. On unusually heavy volume the shares traded in a range of $.21 to $.39 during the day.
Interest Rate Decision Hasn't Phased Micro Cap Stocks
ACCESSWIRE - Wed Sep 09, 11:21AM CDT
CORAL GABLES, FL / ACCESSWIRE / September 9, 2015 / This has been a looming issue for the better part of the last few months: The Fed's decision on what to do about interest rates in the US. The decision will be made known next week but according to some, the real "drama" that some had expected to see in other markets like the bond or even treasuries may simply be a non-event. Doug Duncan, chief economist for Fannie Mae recently told Yahoo Finance's Mike Santoli, "Expectations for a Fed hike built into futures prices suggest there's still only something like 30% chance assigned to a September move. If the Fed wants market expectations more aligned with its policy intentions before a rate change, then you would make the argument that they'll put it off."
ORMP: 7.99 (-0.03), LLY: 81.97 (-0.01)
Cell MedX Corp. (CMXC) Enters Into an Option Agreement With Its President and CEO
Marketwired - Tue Aug 11, 5:40PM CDT
Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"
, a development stage company focused on the discovery, development and commercialization of therapeutic devices for patients with diabetes, announced that its Board of Directors has approved the grant of options (the "Options" to purchase up to 2,500,000 shares of common stock to its President and CEO, Mr. Frank E. McEnulty. Cell MedX Corp. (CMXC) Initiates Discussions With Industry Specialists at Worrell Design
Marketwired - Tue Aug 04, 8:02AM CDT
Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"
a development stage company focused on the discovery, development and commercialization of therapeutic devices for patients with diseases such as diabetes, is pleased to advise of entry into discussions with noted multiple award-winning international product design firm, Worrell Design Inc. ("Worrell". Cell MedX Corp. (CMXC) Advances Development Timeline
Marketwired - Mon Jul 20, 8:01AM CDT
Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"
an early development stage company focused on the discovery, development and commercialization of therapeutic devices for patients with diseases such as diabetes is pleased to update the timeline of its previously announced clinical trials regarding its innovative and proprietary technology branded under the trade name e-Balance. Cell MedX plans to commence clinical trials for e-Balance
M2 - Wed Jul 08, 4:56AM CDT
Cell MedX Corp (OTCQB: CMXC) announced on Tuesday that efforts are underway to commence clinical trials of its proprietary technology branded under the trade name e-Balance, designed for the treatment of diabetes.
Cell MedX Corp. (CMXC) Mobilizes Efforts to Commence Clinical Trials
Marketwired - Tue Jul 07, 8:02AM CDT
Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"
is pleased to announce that efforts are underway to commence clinical trials of its innovative and proprietary technology branded under the trade name e-Balance. Designed for the treatment of diabetes, the intent of the upcoming trials is to accurately measure and quantify e-Balance's ability to alter key metabolic pathways targeting improved blood sugar control. 3 Small-Cap Biotech Stocks That Are Challenging the Status Quo
ACCESSWIRE - Mon Jun 29, 8:01AM CDT
WHITEFISH, MT / ACCESSWIRE / June 29, 2015 / Small-cap biotech stocks have been top performers so far this year, with the PowerShares S&P SmallCap Healthcare ETF (NASDAQ: PSCH) returning 25%, which is 5x better than the SPDR S&P 500 ETF's (NYSE: SPY) 5% return. Investors may want to consider adding exposure to this asset class given its outperformance and lower correlation with the overall U.S. equity market.
SPY: 216.65 (unch), PSCH: 73.91 (+0.21), AXDX: 19.54 (-0.10)
Cell MedX Corp. (CMXC) Engages TDM Financial to Generate Awareness
Marketwired - Thu Jun 25, 8:01AM CDT
Cell MedX Corp. (OTCQB: CMXC), (the "Company"
is pleased to announce it has retained TDM Financial to provide marketing, outreach, and consulting services. TDM Financial owns and operates the SECFilings.com website, a leading financial network with over 600,000 registered members. Cell MedX Corp. (CMXC) Announces Additional Results of Preliminary Analysis of Metabolomic Assays in Phase 1 Pilot Clinical Trial
Marketwired - Mon Apr 13, 7:01AM CDT
Cell MedX Corp. (OTCQB: CMXC), (the "Company"
is pleased to announce additional results of the ongoing analysis of metabolomic assays taken during the Phase 1 pilot clinical trial. Penny Stocks Research for WINDSTREAM, Fastfunds Financial, ScripsAmerica, OSL Holdings, AVRA, and Cell MedX
PR Newswire - Fri Apr 10, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: WINDSTREAM (OTCMKTS:WSTI), Fastfunds Financial (OTCMKTS:FFFC), ScripsAmerica (OTCMKTS:SCRC), OSL Holdings (OTCMKTS:OSLH), AVRA (OTCBB:AVRN), and Cell MedX (OTCBB:CMXC).
Cell MedX begins trading on OTCQB venture stage marketplace from 18 February
M2 - Thu Feb 19, 6:31AM CST
Cell MedX Corp (OTC PINK: CMXC) (OTCQB: CMXC) announced on Wednesday the receipt of an approval from the OTC Markets to upgrade to the OTCQB venture stage marketplace.
Cell MedX Corp. (CMXC) Disavows Coverage by The Moskowitz Report and The SmallCap Network
Marketwired - Tue Jan 27, 2:58PM CST
Cell MedX Corp. (OTC PINK: CMXC), (the "Company"
has become aware of a paid report on the Company prepared and published by The Moskowitz Report dated Winter 2015, and additional reports on the Company prepared by James E. Brumley as a contributor for, and published by, the Small Cap Network dated January 13, 2015, January 21, 2015, and January 26, 2015. The Company believes that the above referenced reports do not provide an accurate portrayal of the Company, its business or its future prospects. Furthermore, the Company has not approved, authorized or participated in the creation of the reports prepared and published by The Moskowitz Report, the Small Cap Network, or any other third parties. The Company advises investors not to rely on these reports for information regarding the Company. Cell MedX engages The Metabolomics Innovation Centre to explore metabolic foundations of diabetes management platform
M2 - Tue Jan 27, 3:37AM CST
Cell MedX Corp (OTC: CMXC), an early development stage company focused on the discovery, development and commercialisation of therapeutic products to help manage the illness and related complications of diseases like diabetes, announced on Monday that it has engaged the Metabolomics Innovation Centre at the University of Alberta (TMIC) to conduct metabolomics profiling of blood samples collected during the discovery phase of the pilot trial, which it commenced on 9 January 2015.
